These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 11690721)

  • 1. LKM1 antibody and interferon therapy in children with chronic hepatitis C.
    Iorio R; Giannattasio A; Vespere G; Vegnente A
    J Hepatol; 2001 Nov; 35(5):685-7. PubMed ID: 11690721
    [No Abstract]   [Full Text] [Related]  

  • 2. [Disappearance of serum autoantibodies during treatment with interferon alpha in a patient with chronic hepatitis C].
    Khemissa F; Bauget P; Michel H; Larrey D
    Gastroenterol Clin Biol; 1997; 21(12):998-9. PubMed ID: 9587568
    [No Abstract]   [Full Text] [Related]  

  • 3. Low virological response to interferon in children with chronic hepatitis C.
    Pensati P; Iorio R; Botta S; Tuccillo C; Donetto S; Vajro P; Ciarlo G; Vegnente A
    J Hepatol; 1999 Oct; 31(4):604-11. PubMed ID: 10551382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact of non-organ-specific autoantibodies on the response to combined antiviral treatment in patients with hepatitis C.
    Muratori P; Muratori L; Guidi M; Granito A; Susca M; Lenzi M; Bianchi FB
    Clin Infect Dis; 2005 Feb; 40(4):501-7. PubMed ID: 15712070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-organ-specific autoantibodies in hepatitis C virus infection: do they matter?
    Bogdanos DP; Mieli-Vergani G; Vergani D
    Clin Infect Dis; 2005 Feb; 40(4):508-10. PubMed ID: 15712071
    [No Abstract]   [Full Text] [Related]  

  • 6. Thyroid dysfunction in antiviral therapy of chronic hepatitis C.
    Dabrowska MM; Panasiuk A; Flisiak R
    Hepatogastroenterology; 2010; 57(101):826-31. PubMed ID: 21033237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Organ-specific autoimmunity and genetic predisposition in interferon-treated HCV-related chronic hepatitis patients.
    Floreani A; Chiaramonte M; Greggio NA; Fabris P; De Lazzari F; Naccarato R; Betterle C
    Ital J Gastroenterol Hepatol; 1998 Feb; 30(1):71-6. PubMed ID: 9615270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon and ribavirin therapy in dialysis patients with chronic hepatitis C.
    Bruchfeld A; Ståhle L; Andersson J; Schvarcz R
    Nephrol Dial Transplant; 2001 Aug; 16(8):1729. PubMed ID: 11477195
    [No Abstract]   [Full Text] [Related]  

  • 9. Characteristics of chronic hepatitis C and response to interferon therapy in older patients.
    Hervé S; Savoye G; Riachi G; Capet C; Goria O; Lerebours E; Colin R
    Age Ageing; 2001 Jul; 30(4):355-6. PubMed ID: 11509317
    [No Abstract]   [Full Text] [Related]  

  • 10. Exacerbation of psoriasis by interferon-alpha therapy for hepatitis C.
    Downs AM; Dunnill MG
    Clin Exp Dermatol; 2000 Jun; 25(4):351-2. PubMed ID: 10971502
    [No Abstract]   [Full Text] [Related]  

  • 11. Regression of hepatic fibrosis and cirrhosis in patients with chronic hepatitis C treated with interferon-based therapy.
    Metwally MA; Zein CO; Zein NN
    Gastroenterology; 2003 May; 124(5):1561. PubMed ID: 12760398
    [No Abstract]   [Full Text] [Related]  

  • 12. Sustained remission of chronic hepatitis C after a change to human leukocyte interferon-alpha in a difficult-to-treat patient with breakthrough phenomenon associated with antibodies against recombinant interferon-alpha.
    Berg T; Hopf U; Schuff-Werner P
    Am J Gastroenterol; 2001 Feb; 96(2):612-4. PubMed ID: 11232730
    [No Abstract]   [Full Text] [Related]  

  • 13. Difficulties in conducting large-scale studies on rare diseases: the case for pediatric hepatitis C infection.
    Süoglu OD
    J Pediatr Gastroenterol Nutr; 2002 Aug; 35(2):235. PubMed ID: 12187309
    [No Abstract]   [Full Text] [Related]  

  • 14. Adding ribavirin to interferon alpha-2b for chronic hepatitis C infection increased virological response and nausea.
    Schalm SW
    Gut; 1998 Nov; 43(5):602. PubMed ID: 9824337
    [No Abstract]   [Full Text] [Related]  

  • 15. Sustained virological response after a short course of treatment with interferon and ribavirin in two chronic hepatitis C patients.
    Nousbaum JB; Cadranel JF; Savary O; Legrand MC; Dumouchel P; Gouérou H
    J Hepatol; 2003 Oct; 39(4):655-6. PubMed ID: 12971981
    [No Abstract]   [Full Text] [Related]  

  • 16. New interferon alfa formulation licensed for treatment of hepatitis C.
    Thompson CA
    Am J Health Syst Pharm; 2001 Mar; 58(6):452. PubMed ID: 11286138
    [No Abstract]   [Full Text] [Related]  

  • 17. [Significance of non-organ-specific autoantibodies in HCV-related chronic hepatitis].
    Guidi M; Muratori P; Granito A; Muratori L; Pappas G; Bianchi FB
    Recenti Prog Med; 2005 Dec; 96(12):589-93. PubMed ID: 16496742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble interleukin 2 receptor plasma levels in non-responders with chronic hepatitis C treated with pegylated interferon-alpha 2b and ribavirin.
    Henke H; Schmiegel W; Brechmann T; Voigt E; Griga T
    J Clin Gastroenterol; 2004 Mar; 38(3):301-3. PubMed ID: 15128086
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost effectiveness of pegylated interferon alpha 2b and ribavirin combination in chronic hepatitis C.
    Poynard T
    Gut; 2003 Oct; 52(10):1532. PubMed ID: 12970155
    [No Abstract]   [Full Text] [Related]  

  • 20. [Efficacy of combination therapy with pegylated-interferon alfa-2a plus ribavirin in autoantibody-positive chronic hepatitis C patients].
    Li YX; Yang YJ; Yang M; Chen LY; Lu JJ; Ma YJ; Liu K; Lei XZ; Tang H
    Zhonghua Gan Zang Bing Za Zhi; 2013 May; 21(5):345-7. PubMed ID: 24025134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.